{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T18:10:25Z","timestamp":1773425425164,"version":"3.50.1"},"reference-count":68,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Objective<\/jats:title><jats:p>In recent years, studies of drug-eluting stent (DES) for femoropopliteal artery diseases (FPADs) have been gradually published. To explore whether this type of stent is superior to the traditional bare metal stent (BMS), we performed this study.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>A systematic search for randomized controlled trials (RCTs) in Excerpta Medica Database (Embase), PubMed, Web of Science (WOS), and Cochrane Library was performed on November 29, 2022. We innovatively adopted the hazard ratio (HR), the most appropriate indicator, as a measure of the outcomes that fall under the category of time-to-event data. The HRs was extracted directly or indirectly. Then, the meta-analyses using random effects model were performed. The bias risks of included papers were assessed by the Cochrane Risk of Bias 2.0 tool. This study was registered on the PROSPER platform (CRD42023391944) and not funded.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>Seven RCTs involving 1,889 participants were found. After pooled analyses, we obtained results without propensity on each of the following 3 outcomes of interest: in-stent restenosis (ISR) -free survival, primary patency (PP) survival, and target lesion revascularization (TLR) -free survival (P &gt;0.05, respectively). Because the results of pooled analyses of the other two outcomes of interest (all-cause death free survival and clinical benefit survival) had high heterogeneity both, they were not accepted by us.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusion<\/jats:title><jats:p>For FPADs, the DES has not yet demonstrated superiority or inferiority to BMS, in the ability to maintain PP, avoid ISR and TLR.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0291466","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T17:31:25Z","timestamp":1695317485000},"page":"e0291466","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Meta-analysis of outcomes from drug-eluting stent implantation in femoropopliteal arteries"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0473-5667","authenticated-orcid":true,"given":"Mingxuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixia","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangliang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengchen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"pone.0291466.ref001","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"JP Higgins","year":"2011","journal-title":"BMJ"},{"issue":"S","key":"pone.0291466.ref002","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).","volume":"45","author":"L Norgren","year":"2007","journal-title":"J Vasc Surg"},{"issue":"5","key":"pone.0291466.ref003","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.jvs.2011.09.001","article-title":"2011 ACCF\/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines.","volume":"54","author":"TW Rooke","year":"2011","journal-title":"J Vasc Surg"},{"issue":"3","key":"pone.0291466.ref004","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1161\/CIRCULATIONAHA.115.018034","article-title":"Drug-Eluting Stents Are the Default Strategy for Superficial Femoral Artery Intervention Now","volume":"133","author":"MW Burket","year":"2016","journal-title":"Circulation"},{"issue":"Pt 1","key":"pone.0291466.ref005","first-page":"133","article-title":"Arterial tortuosity in the femoropopliteal region during knee flexion: a magnetic resonance angiographic study","volume":"187","author":"PJ Wensing","year":"1995","journal-title":"J Anat"},{"issue":"6","key":"pone.0291466.ref006","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.RVI.0000220367.62137.E8","article-title":"In vivo MR angiographic quantification of axial and twisting deformations of the superficial femoral artery resulting from maximum hip and knee flexion","volume":"17","author":"CP Cheng","year":"2006","journal-title":"J Vasc Interv Radiol"},{"issue":"18","key":"pone.0291466.ref007","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa051303","article-title":"Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery","volume":"354","author":"M Schillinger","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0291466.ref008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1583\/11-3627.1","article-title":"Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial.","volume":"19","author":"JR Laird","year":"2012","journal-title":"J Endovasc Ther"},{"issue":"7","key":"pone.0291466.ref009","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/ccd.22128","article-title":"Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions","volume":"74","author":"P Dick","year":"2009","journal-title":"Catheter Cardiovasc Interv"},{"issue":"21","key":"pone.0291466.ref010","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1161\/CIRCULATIONAHA.107.688341","article-title":"Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting","volume":"115","author":"M Schillinger","year":"2007","journal-title":"Circulation"},{"issue":"4","key":"pone.0291466.ref011","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/ccd.25510","article-title":"12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty","volume":"84","author":"K Marmagkiolis","year":"2014","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"pone.0291466.ref012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1583\/13-4399MR.1","article-title":"Nitinol self-expanding stents vs. balloon angioplasty for very long femoropopliteal lesions","volume":"21","author":"EJ Armstrong","year":"2014","journal-title":"J Endovasc Ther"},{"issue":"1","key":"pone.0291466.ref013","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ccd.25895","article-title":"A single stent strategy in patients with lifestyle limiting claudication: 3-year results from the Durability II trial.","volume":"86","author":"KJ Rocha-Singh","year":"2015","journal-title":"Catheter Cardiovasc Interv"},{"issue":"4","key":"pone.0291466.ref014","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcin.2019.12.028","article-title":"A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.","volume":"13","author":"Y Gou\u00ebffic","year":"2020","journal-title":"JACC Cardiovasc Interv."},{"issue":"7","key":"pone.0291466.ref015","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3390\/jcm9072221","article-title":"Assessment of Mortality and Factors Affecting Outcome of Use of Paclitaxel-Coated Stents and Bare Metal Stents in Femoropopliteal PAD.","volume":"9","author":"A Falkowski","year":"2020","journal-title":"J Clin Med."},{"issue":"15","key":"pone.0291466.ref016","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","article-title":"Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial","volume":"133","author":"MD Dake","year":"2016","journal-title":"Circulation"},{"issue":"9","key":"pone.0291466.ref017","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00380-017-0982-7","article-title":"Penetration rate of the placement of a drug-eluting stent for the treatment of superficial femoral artery lesions in Japan.","volume":"32","author":"S Mori","year":"2017","journal-title":"Heart Vessels"},{"key":"pone.0291466.ref018","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/1467-985X.00207","article-title":"The value of the aggregate data approach in meta-analysis with time-to-event outcomes","volume":"164","author":"C Tudur","year":"2001","journal-title":"Journal of the Royal Statistical Society A"},{"key":"pone.0291466.ref019","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis.","volume":"8","author":"JF Tierney","year":"2007","journal-title":"Trials"},{"issue":"24","key":"pone.0291466.ref020","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.","volume":"17","author":"MKB Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"22","key":"pone.0291466.ref021","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time-to-event outcomes.","volume":"21","author":"PR Williamson","year":"2002","journal-title":"Stat Med."},{"key":"pone.0291466.ref022","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JAC Sterne","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"pone.0291466.ref023","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update.","volume":"28","author":"R DerSimonian","year":"2007","journal-title":"Contemp Clin Trials"},{"issue":"404","key":"pone.0291466.ref024","first-page":"1014","article-title":"Newton-Raphson and EM Algorithms for Linear Mixed-Effects Models for Repeated-Measures Data","volume":"83","author":"MJ Lindstrom","year":"1988","journal-title":"J Am Stat Assoc"},{"key":"pone.0291466.ref025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"DR Cox","year":"1972","journal-title":"Journal of the Royal Statistical Society (B)."},{"issue":"9","key":"pone.0291466.ref026","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/sim.2010","article-title":"A method for meta-analysis of molecular association studies.","volume":"24","author":"A Thakkinstian","year":"2005","journal-title":"Stat Med"},{"issue":"11","key":"pone.0291466.ref027","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/sim.4780101105","article-title":"A general parametric approach to the meta-analysis of randomized clinical trials.","volume":"10","author":"A Whitehead","year":"1991","journal-title":"Stat Med"},{"issue":"7109","key":"pone.0291466.ref028","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ"},{"key":"pone.0291466.ref029","first-page":"323","article-title":"Bias in meta-analysis and funnel plot asymmetry.","volume":"68","author":"M Biljana","year":"1999","journal-title":"Stud Health Technol Inform"},{"issue":"7650","key":"pone.0291466.ref030","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"GH Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"6","key":"pone.0291466.ref031","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1583\/05-1704.1","article-title":"Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial","volume":"13","author":"SH Duda","year":"2006","journal-title":"J Endovasc Ther"},{"issue":"8","key":"pone.0291466.ref032","doi-asserted-by":"crossref","first-page":"e006564","DOI":"10.1161\/CIRCINTERVENTIONS.118.006564","article-title":"Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in the Treatment of the Superficial Femoral Artery.","volume":"11","author":"T Miura","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"issue":"21","key":"pone.0291466.ref033","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1161\/CIRCULATIONAHA.122.059606","article-title":"Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial","volume":"146","author":"Y Gou\u00ebffic","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"pone.0291466.ref034","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/01.CIR.0000029746.10018.36","article-title":"Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results","volume":"106","author":"SH Duda","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"pone.0291466.ref035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.RVI.0000151260.74519.CA","article-title":"Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial","volume":"16","author":"SH Duda","year":"2005","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"pone.0291466.ref036","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/CIRCULATIONAHA.107.689141","article-title":"Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST).","volume":"116","author":"H Krankenberg","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"pone.0291466.ref037","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/0735-1097(95)00249-4","article-title":"Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis","volume":"26","author":"GR Dussaillant","year":"1995","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"pone.0291466.ref038","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jvs.2012.12.066","article-title":"The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Prot\u00e9g\u00e9 EverfLex NitInol STent SYstem II (DURABILITY II).","volume":"58","author":"JS Matsumura","year":"2013","journal-title":"J Vasc Surg"},{"issue":"8","key":"pone.0291466.ref039","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1161\/01.CIR.95.8.1998","article-title":"Histopathology of in-stent restenosis in patients with peripheral artery disease","volume":"95","author":"M Kearney","year":"1997","journal-title":"Circulation"},{"issue":"3","key":"pone.0291466.ref040","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","article-title":"A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization","volume":"346","author":"MC Morice","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0291466.ref041","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/01.CIR.0000047700.58683.A1","article-title":"TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions","volume":"107","author":"E Grube","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"pone.0291466.ref042","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.113.001790","article-title":"Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans","volume":"129","author":"F Otsuka","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"pone.0291466.ref043","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"FJ Neumann","year":"2019","journal-title":"Eur Heart J"},{"issue":"2","key":"pone.0291466.ref044","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1538574416689426","article-title":"Systematic Review and Meta-Analysis of Drug-Eluting Balloon and Stent for Infrapopliteal Artery Revascularization.","volume":"51","author":"J Zhang","year":"2017","journal-title":"Vasc Endovascular Surg"},{"issue":"1","key":"pone.0291466.ref045","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1526602815622953","article-title":"Propensity Score Analysis Comparing Clinical Outcomes of Drug-Eluting vs Bare Nitinol Stents in Femoropopliteal Lesions.","volume":"23","author":"Y Soga","year":"2016","journal-title":"J Endovasc Ther."},{"issue":"2","key":"pone.0291466.ref046","first-page":"130","article-title":"Real-World Comparison of Drug-Eluting and Bare-Metal Stents in Superficial Femoral Artery Occlusive Disease with Trans-Atlantic Intersociety Consensus B Lesions: A 2-Year, Single-Institute Study.","volume":"34","author":"FC Meng","year":"2018","journal-title":"Acta Cardiol Sin."},{"key":"pone.0291466.ref047","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.avsg.2017.12.003","article-title":"Comparison of Drug-Eluting Stent with Bare-Metal Stent Implantation in Femoropopliteal Artery Disease: A Systematic Review and Meta-Analysis.","volume":"50","author":"Y Ding","year":"2018","journal-title":"Ann Vasc Surg"},{"issue":"5","key":"pone.0291466.ref048","first-page":"546","article-title":"Angioplasty or bare metal stent versus drug-eluting endovascular treatment in femoropopliteal artery disease: a systematic review and meta-analysis","volume":"60","author":"G Varetto","year":"2019","journal-title":"J Cardiovasc Surg (Torino)."},{"key":"pone.0291466.ref049","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.avsg.2016.10.058","article-title":"Bare Metal Versus Paclitaxel-Eluting Stents for Long Femoropopliteal Lesions: Prospective Cohorts Comparison Using a Propensity Score-Matched Analysis.","volume":"43","author":"PA Vent","year":"2017","journal-title":"Ann Vasc Surg."},{"issue":"4","key":"pone.0291466.ref050","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jvs.2012.04.046","article-title":"Supervised walking therapy in patients with intermittent claudication","volume":"56","author":"F Fakhry","year":"2012","journal-title":"J Vasc Surg"},{"issue":"1","key":"pone.0291466.ref051","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/bjs.7710","article-title":"Randomized clinical trial of percutaneous transluminal angioplasty, supervised exercise and combined treatment for intermittent claudication due to femoropopliteal arterial disease.","volume":"99","author":"FA Mazari","year":"2012","journal-title":"Br J Surg"},{"issue":"1","key":"pone.0291466.ref052","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/CIRCULATIONAHA.111.075770","article-title":"Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study.","volume":"125","author":"TP Murphy","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"pone.0291466.ref053","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jcin.2015.03.022","article-title":"1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.","volume":"8","author":"O Iida","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"pone.0291466.ref054","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1583\/13-4630MR.1","article-title":"Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions","volume":"21","author":"T Zeller","year":"2014","journal-title":"J Endovasc Ther"},{"issue":"3","key":"pone.0291466.ref055","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1526602818762805","article-title":"Full Drug-Eluting Stent Jacket: Two-Year Results of a Single-Center Experience With Zilver PTX Stenting for Long Lesions in the Femoropopliteal Arteries.","volume":"25","author":"JA Phillips","year":"2018","journal-title":"J Endovasc Ther."},{"issue":"2","key":"pone.0291466.ref056","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jvs.2016.09.031","article-title":"Diagnosis, classification, and treatment of femoropopliteal artery in-stent restenosis","volume":"65","author":"KJ Ho","year":"2017","journal-title":"J Vasc Surg"},{"issue":"3","key":"pone.0291466.ref057","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4070\/kcj.2018.0074","article-title":"Treatment of Femoropopliteal Artery In-stent Restenosis.","volume":"48","author":"W Kim","year":"2018","journal-title":"Korean Circ J"},{"issue":"3","key":"pone.0291466.ref058","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jcin.2012.12.118","article-title":"Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.","volume":"6","author":"T Zeller","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"pone.0291466.ref059","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/1526602816639721","article-title":"Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.","volume":"23","author":"Y Tomoi","year":"2016","journal-title":"J Endovasc Ther."},{"issue":"10157","key":"pone.0291466.ref060","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(18)32262-1","article-title":"A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.","volume":"392","author":"WA Gray","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"pone.0291466.ref061","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jvs.2011.01.047","article-title":"First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease","volume":"54","author":"J Lammer","year":"2011","journal-title":"J Vasc Surg"},{"issue":"16","key":"pone.0291466.ref062","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.jacc.2011.02.016","article-title":"A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.","volume":"57","author":"GW Stone","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"pone.0291466.ref063","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.jcin.2017.06.070","article-title":"Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial.","volume":"10","author":"CR Kelly","year":"2017","journal-title":"JACC Cardiovasc Interv."},{"issue":"6","key":"pone.0291466.ref064","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jcin.2022.01.019","article-title":"1-Year Outcomes of Fluoropolymer-Based Drug-Eluting Stent in Femoropopliteal Practice: Predictors of Restenosis and Aneurysmal Degeneration.","volume":"15","author":"O Iida","year":"2022","journal-title":"JACC Cardiovasc Interv."},{"issue":"2","key":"pone.0291466.ref065","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/1526602820901723","article-title":"Effectiveness and Safety of a Paclitaxel-Eluting Stent for Superficial Femoral Artery Lesions up to 190 mm: One-Year Outcomes of the Single-Arm IMPERIAL Long Lesion Substudy of the Eluvia Drug-Eluting Stent.","volume":"27","author":"J Golzar","year":"2020","journal-title":"J Endovasc Ther."},{"issue":"12","key":"pone.0291466.ref066","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s00270-017-1771-5","article-title":"Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up.","volume":"40","author":"S M\u00fcller-H\u00fclsbeck","year":"2017","journal-title":"Cardiovasc Intervent Radiol."},{"issue":"2","key":"pone.0291466.ref067","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5551\/jat.50369","article-title":"One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease.","volume":"27","author":"Y Soga","year":"2020","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"pone.0291466.ref068","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1080\/13696998.2022.2088965","article-title":"Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention.","volume":"25","author":"WA Gray","year":"2022","journal-title":"J Med Econ."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T17:01:50Z","timestamp":1730134910000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291466"}},"subtitle":[],"editor":[{"given":"Redoy","family":"Ranjan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":68,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0291466","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}